Zobrazeno 1 - 10
of 881
pro vyhledávání: '"Efflux pump inhibitors"'
Publikováno v:
Microbial Cell, Vol 11, Pp 368-377 (2024)
Staphylococcus aureus, a versatile human pathogen, poses a significant challenge in healthcare settings due to its ability to develop antibiotic resistance and form robust biofilms. Understanding the intricate mechanisms underlying the antibiotic res
Externí odkaz:
https://doaj.org/article/a0767d2676544d91ada3fe0a86a4c252
Publikováno v:
Novel Research in Microbiology Journal, Vol 8, Iss 4, Pp 2526-2541 (2024)
Globally, there is a growing concern about Pseudomonas aeruginosa resistance to aminoglycosides. Enzymatic modification of these drugs is the predominant resistance mechanism. Additionally, P. aeruginosa possesses many efflux systems that enable it
Externí odkaz:
https://doaj.org/article/6878f6e3037f445ebd966e7058feecfe
Autor:
Hadeel Qasim Jebur, Alaa H Al-Charrakh
Publikováno v:
Medical Journal of Babylon, Vol 21, Iss 1, Pp 179-185 (2024)
Background: One of the efflux pump inhibitors is carbonyl cyanide 3-chlorophenylhydrazone (CCCP) that has often been found to increase the susceptibility of a number of multi-drug resistant (MDR) MDR bacteria, isolated from human clinical specimens.O
Externí odkaz:
https://doaj.org/article/d73c2deb64f54c26b16f3f2d576da76d
Autor:
Irianti, Marina Ika a, b, Malloci, Giuliano c, Ruggerone, Paolo c, Lodinsky, Eszter Valéria d, Vincken, Jean-Paul a, Pos, Klaas Martinus d, ⁎, Araya-Cloutier, Carla a, ⁎
Publikováno v:
In Biomedicine & Pharmacotherapy January 2025 182
Autor:
da Cunha, Ieda Vieira a, da Silva Oliveira, Douglas Davison a, Calefi, Gabriel Guimarães b, Silva, Nagela Bernadelli Sousa b, Martins, Carlos Henrique Gomes b, Rezende Júnior, Celso de Oliveira a, Tsubone, Tayana Mazin a, ⁎
Publikováno v:
In European Journal of Medicinal Chemistry 15 February 2025 284
Publikováno v:
BMC Microbiology, Vol 24, Iss 1, Pp 1-13 (2024)
Abstract Resistance mechanisms are a shelter for Acinetobacter baumannii to adapt to our environment which causes difficulty for the infections to be treated and WHO declares this organism on the top of pathogens priority for new drug development. Th
Externí odkaz:
https://doaj.org/article/0eb9ece96c6d4cecaed025ab2740f9bd
Autor:
Maša Zorman, Maja Kokot, Irena Zdovc, Lidija Senerovic, Mina Mandic, Nace Zidar, Andrej Emanuel Cotman, Martina Durcik, Lucija Peterlin Mašič, Nikola Minovski, Marko Anderluh, Martina Hrast Rambaher
Publikováno v:
Antibiotics, Vol 13, Iss 11, p 1081 (2024)
Background: The novel bacterial topoisomerase inhibitors (NBTIs) developed in our laboratory show potent on-target enzyme inhibition but suffer from low activity against Gram-negative bacteria. Methods: With the aim of improving the antibacterial act
Externí odkaz:
https://doaj.org/article/18648e60153942908aeb787e7baf01d1
Publikováno v:
Academic Science Journal, Vol 2, Iss 3 (2024)
• baumannii considered one important pathogenic bacteria and responsible for several nosocomial and community infections for human and , possess the ability to form biofilms , and continued development of antibiotic resistance to drugs used to trea
Externí odkaz:
https://doaj.org/article/c7ae6590c4c54374b1f58ee19b5c004c
Autor:
Muhammad Asim, Yasin Ahmad, Momin Khan, Zeeshan Ahmad, Awais Khalid, Pervaiz Ahmad, Abdulhameed Khan, Fakhrul Ahsan, Mohsin Kazi, Samer H. Zyoud
Publikováno v:
Heliyon, Vol 10, Iss 13, Pp e33749- (2024)
Background: There is increasing emphasis on restoring the efficacy of existing antibiotics instead of developing new ones. Objectives: This study aimed to determine the role of Cremophor EL and Cremophor RH40 in the inhibition of efflux pumps in MDR
Externí odkaz:
https://doaj.org/article/af03725a59604caaad26262878764c82
Autor:
Mousumi Shyam, Abhishek Thakur, Caroline Velez, Chris Daniel, Orlando Acevedo, Sanjib Bhakta, Venkatesan Jayaprakash
Publikováno v:
Frontiers in Antibiotics, Vol 3 (2024)
IntroductionIn response to continued public health emergency of antimicrobial resistance (AMR), a significant key strategy is the discovery of novel mycobacterial efflux-pump inhibitors (EPIs) as potential adjuvants in combination drug therapy. Inter
Externí odkaz:
https://doaj.org/article/e0ba094b968c42ef87eafcf5d71e033f